Neuralstem, Inc. | |||
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss | |||
Three Months Ended March 31, | |||
2019 | 2018 | ||
Revenues | $ 2,500 | $ 2,500 | |
Operating expenses: | |||
Research and development expenses | 1,514,463 | 1,169,441 | |
General and administrative expenses | 944,602 | 1,182,054 | |
Total operating expenses | 2,459,065 | 2,351,495 | |
Operating loss | (2,456,565) | (2,348,995) | |
Other income (expense): | |||
Interest income | 29,000 | 17,749 | |
Interest expense | (2,017) | (1,920) | |
Change in fair value of derivative instruments | (340,115) | 190,219 | |
Other income (expense) | (344,295) | (4,021) | |
Total other income (expense) | (657,427) | 202,027 | |
Net loss | $ (3,113,992) | $ (2,146,968) | |
Net loss per share - basic and diluted | $ (0.17) | $ (0.14) | |
Weighted average common shares outstanding - basic | 18,216,421 | 15,116,937 | |
Comprehensive loss: | |||
Net loss | $ (3,113,992) | $ (2,146,968) | |
Foreign currency translation adjustment | (1,743) | 115 | |
Comprehensive loss | $ (3,115,735) | $ (2,146,853) |